Can Alcon turn baseball fandom into a growth engine for Systane in Canada’s dry eye category?
See how Alcon is using the Toronto Blue Jays to expand Systane’s dry eye reach in Canada and what it means for eye care competition.
Pharma & Biotech
Pharma & Biotech
Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.